| BCBS Highmark West Virginia | Paclitaxel, albumin-bound (Abraxane) | 2025-10-01 |
| BCBS Highmark West Virginia | Margetuximab-cmkb (Margenza) | 2025-10-01 |
| BCBS Highmark West Virginia | Revakinagene taroretcel-lwey (Encelto) | 2025-10-01 |
| BCBS Highmark NY and West NY | Datopotamab deruxtecan-dlnk (Datroway) | 2025-10-01 |
| BCBS Highmark NY and West NY | Fulvestrant (Faslodex) | 2025-10-01 |
| HealthPartners | Oncology ** - denosumab and biosimilars | 2025-10-01 |
| UHC Commercial Medical & Drug | Antiemetics for Oncology – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Cosentyx® (Secukinumab) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Encelto™ (Revakinagene Taroretcel-Lwey) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Ilumya® (Tildrakizumab-Asmn) – Commercial Medical Benefit Drug Policy | 2025-10-01 |